6-甲氧基-3-硝基喹啉-4-醇 | 628284-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-甲氧基-3-硝基喹啉-4-醇
• 英文名称: 6-methoxy-3-nitroquinolin-4-ol
• 英文别名: 6-Methoxy-3-nitro-chinolin-4-ol；6-methoxy-3-nitro-1H-quinolin-4-one
• CAS: 628284-89-9
• 化学式: C₁₀H₈N₂O₄
• 分子量: 220.185
• InChiKey: WWYMTCLDNGUQFF-UHFFFAOYSA-N

物化性质

• 熔点：
  >325 °C
• 沸点：
  372.7±37.0 °C(Predicted)
• 密度：
  1.457±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  6-甲氧基-3-硝基喹啉-4-醇 在 platinum on activated charcoal 过氧乙酸 、 氯化亚砜 、 氢气 、 magnesium sulfate 、 三乙胺 、 N,N-二甲基甲酰胺 、 三氯氧磷 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and Structure−Activity-Relationships of 1H-Imidazo[4,5-c]quinolines That Induce Interferon Production

  摘要：

  1H-Imidazo-[4,5-c]quinolines were prepared while investigating novel nucleoside analogues as potential antiviral agents. While these compounds showed no direct antiviral activity when tested in a number of cell culture systems, some demonstrated potent inhibition of virus lesion development in an intravaginal guinea pig herpes simplex virus-2 assay. We have determined that the in vivo antiviral activity can be attributed to the ability of these molecules to induce the production of cytokines, especially interferon (IFN), in this model. Subsequently, we found that the compounds also induce in vitro production of IFN in human peripheral blood mononuclear cells (hPBMCs). The in vitro results reported herein and the in vivo results reported previously led to the discovery of imiquimod, 26, which was developed as a topical agent and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.

  DOI：

  10.1021/jm049211v
• 作为产物：
  描述：

  5-methoxy-2-(2-nitro-ethylidenamino)-benzoic acid 在 sodium acetate 、 乙酸酐 作用下， 生成 6-甲氧基-3-硝基喹啉-4-醇
  参考文献：
  名称：

  3-硝基-4-羟基喹啉的喹啉衍生物。

  摘要：

  DOI：

  10.1021/ja01194a060

文献信息

• Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20170073343A1

  公开（公告）日：2017-03-16

  The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R 1 , R 1a , R 1b , R 2 , R 4 , R 5 , R 6 , X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了新颖的咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啉衍生物的化合物(I)及其药学上可接受的盐，其中R1、R1a、R1b、R2、R4、R5、R6、X和Z如规范中所定义。该发明还涉及包含化合物(I)的药物组合物，以及利用这些化合物治疗与LRRK2相关的疾病，如神经退行性疾病包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• Synthesis and Structure−Activity Relationships of Fused Imidazopyridines:  A New Series of Benzodiazepine Receptor Ligands
  作者：Susumu Takada、Takashi Sasatani、Nobuo Chomei、Makoto Adachi、Toshio Fujishita、Masami Eigyo、Shunji Murata、Kazuo Kawasaki、Akira Matsushita

  DOI：10.1021/jm9600609

  日期：1996.1.1

  synthesized and evaluated as benzodiazepine receptor ligands. Affinity to the receptors was greatly affected by the bulkiness of the aryl group at the 2-position, compared to the pyrazoloquinolines such as CGS-9896. Derivatives with an isoxazole moiety at the 2-position showed high binding affinity and in vivo activity. In the imidazo[4,5-c]quinoline series, substitution at the 6-position decreased or abolished

  合成了2-Arylimidazo [4,5-c]喹啉和类似的稠合咪唑并吡啶，并评价为苯并二氮杂receptor受体配体。与吡唑并喹啉如CGS-9896相比，与受体的亲和力受2-位芳基庞大性的影响。在2-位具有异恶唑部分的衍生物显示出高结合亲和力和体内活性。在咪唑并[4,5-c]喹啉系列中，在6-位的取代降低或消除了活性。除7-卤代类似物外，大多数具有未取代异恶唑基的衍生物均表现出拮抗或反向激动剂活性。另一方面，5-甲基异恶唑-3-基或3-甲基异恶唑-5-基衍生物通常表现出激动剂活性。在与非芳族环稠合的咪唑并吡啶中观察到对异恶唑部分的类似取代作用。根据详细的药理评估，S-8510，2-（3-异恶唑基）-3,6,7,9-四氢咪唑并[4,5-d]吡喃++ + [4,3-b]吡啶一磷酸具有弱的反向激动剂选择活性作为治疗老年性痴呆某些症状的治疗候选药物。
• 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
  申请人：Garcia-Echeverria Carlos

  公开号：US20050245562A1

  公开（公告）日：2005-11-03

  The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

  本发明涉及咪唑喹啉及其盐在治疗蛋白激酶依赖性疾病以及制备治疗该类疾病的药物制剂中的应用，咪唑喹啉用于治疗蛋白激酶依赖性疾病，一种治疗该类疾病的方法，包括向温血动物，尤其是人类，给予咪唑喹啉，包含咪唑喹啉的药物制剂，尤其是用于治疗蛋白激酶依赖性疾病的药物制剂，新型咪唑喹啉以及制备新型咪唑喹啉的方法。
• 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
  申请人：Novartis AG

  公开号：US07998972B2

  公开（公告）日：2011-08-16

  The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

  本发明涉及在蛋白激酶依赖性疾病的治疗中使用咪唑喹啉及其盐，并用于制备治疗该类疾病的药物制剂，咪唑喹啉用于治疗蛋白激酶依赖性疾病，一种治疗该类疾病的方法，包括向温血动物，特别是人类，给予咪唑喹啉，包含咪唑喹啉的药物制剂，特别用于治疗蛋白激酶依赖性疾病，新型咪唑喹啉以及制备新型咪唑喹啉的方法。
• Novel synthetic procedures for C2 substituted imidazoquinolines as ligands for the α/β-interface of the GABAA-receptor
  作者：Markus Draskovits、Daniele Catorci、Laurin Wimmer、Sabah Rehman、David Chan Bodin Siebert、Margot Ernst、Michael Schnürch、Marko D. Mihovilovic

  DOI：10.1007/s00706-022-02988-8

  日期：——

  A series of substituted imidazoquinolines, a structurally related chemotype to pyrazoloquinolinones, a well-known class of GABA_A ligands, was prepared via two synthetic procedures and the efficiency of these procedures were compared. One method relies on classical heterocyclic synthesis, the other one aims at late-stage decoration of a truncated scaffold via direct C–H functionalization. A pharmacological evaluation disclosed that one of the synthesized derivatives showed interesting activity on a α1β3 containing receptor subtype.

  Graphical abstract

  摘要 通过两种合成方法制备了一系列取代的咪唑喹啉类化合物，这些化合物在结构上与吡唑喹啉酮类化合物（一类著名的 GABAA 配体）相关，并对这两种方法的效率进行了比较。一种方法依赖于经典的杂环合成，另一种方法旨在通过直接 C-H 功能化对截短的支架进行后期装饰。药理评估显示，合成的一种衍生物对含有α1β3受体亚型的受体具有有趣的活性。 图表摘要